Kidney Transplantation in the Times of COVID-19 – A Literature Review

24 July 2020 : Review article

Ashraf Imam^1ACDEF*, Sadi A. Abukhalaf^1ABCEF, Riham Imam^1BCD, Samir Abu-Gazala^1AEF, Hadar Merhav^1ACD, Abed Khalaileh^1ABCEF

DOI: 10.12659/AOT.925755

Ann Transplant 2020; 25:e925755

Related articles Order reprints Share article Share by email

View HTML version

Table 4 Management and Outcomes of the 58 Reported Kidney Transplant Patients Who Encountered COVID-19.

Variable	Value
Baseline Immunosuppression
Tacrolimus	48/58 (82.7%)
Mycophenolate mofetil	46/58 (79.3%)
Prednisone	47/58 (81%)
Azathioprine	2/58 (3.4%)
Everolimus	3/58 (5.2%)
Ciclosporin	4/58 (6.8%)
Sirolimus	2/58 (3.4%)
Mizoribine	1/58 (1.7%)
Management
Immunosuppression
Held tacrolimus	23/48 (47.9%)
Reduced tacrolimus	10/48 (20.8%)
No change tacrolimus	15/48 (25.8%)
Held mycophenolate mofetil	37/46 (80.4%)
Reduced mycophenolate mofetil	2/46 (4.3%)
No change mycophenolate mofetil	7/46 (15.2%)
Held prednisone	7/47 (14.8%)
Increased prednisone	2/47 (4.2%)
No change prednisone	38/47 (80.8%)
Azathioprine	Held 1; No change 1
Everolimus	Held 2; No change 1
Ciclosporin	Held 2; No change 2
Sirolimus	Held 1; No change 1
Mizoribine	Held 1
Other Tx
Lopinavir/Ritonavir	12/58 (20.6%)
Hydroxychloroquine	25/58 (43.1%)
Azithromycin	9/58 (15.5%)
Oseltamivir	8/58 (13.8%)
Antibiotics	24/58 (41.3%)
Intravenous methylprednisolone	19/58 (32.7%)
Intravenous immunoglobulin	15/58 (25.8%)
Unspecified antivirals	10/58 (17.2%)
Interferon α, β	3/58 (5.2%)
Tocilizumab	2/58 (3.4%)
Remdesivir	1/58 (1.7%)
ICU admission	11/58 (19%)
MV requirement	13/58 (22.4%)
Outcomes
Clinically recovered/Discharged	36/58 (62%)
Illness days duration (median, Range)	17.5 (7–48)
Alive but suffers/In hospital	13/58 (22.4%)
Illness days duration (median, range)	14 (7–49)
Death	9/58 (15.5%)
Illness days duration (median, range)	9 (5–40)

Back to the Article